Avacta Group Plc (AVCT)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Avacta Group Plc (AVCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013109
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Avacta Group Plc (Avacta) is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products which include optim and sensipod. It also develops UCB celltech, which is an analytical instrument. Avacta’s sensipod is an in-clinical blood testing system that delivers ELISA tests. The company offers intellectual property relating to an alternative to antibodies. It develops reagents and diagnostics which are used in affinity chromatography, protein to protein interactions, immunoassay and rapid diagnostic test applications, among others. It operates in Wetherby, Cambridge and London. Avacta is headquartered in Wetherby, the UK.

Avacta Group Plc (AVCT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Avacta Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Avacta Group Plc, Medical Devices Deals, 2011 to YTD 2017 10
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Avacta Group Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Avacta Group Enters into Agreement with Memorial Sloan Kettering Cancer Center 12
Avacta Enters into Agreement with Glythera 13
Avacta Enters Into Agreement With UbiQ Bio For Ubiquitin Affimers 14
Avacta Life Sciences Enters Into Co-Development Agreement With University of Liverpool 15
Avacta Enters Into Co-Marketing Agreement With Pall 16
Avacta Group Enters Into Distribution Agreement With Cold Spring Biotech 17
Licensing Agreements 18
Avacta Enters Into Licensing Agreement With Blueberry Therapeutics For Affimers 18
Equity Offering 19
Avacta Announces Private Placement Of Shares For US$17 Million 19
Avacta Group Announces Private Placement Of Shares For US$8.1 Million 21
Avacta Group Completes Private Placement Of US$3 Million 22
Asset Transactions 23
Unchained Labs Acquires Optim Technology from Avacta for USD5 Million 23
Acquisition 24
Avacta Group Completes Acquisition Of Biotech Company Aptuscan For US$2.3 Million 24
Avacta Group Plc – Key Competitors 25
Avacta Group Plc – Key Employees 26
Avacta Group Plc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 29
Financial Announcements 29
Aug 07, 2017: Avacta Group: Trading Update and Notice of Results 29
Apr 03, 2017: Avacta Group: Interim results for the period ended 31 January 2017 31
Oct 17, 2016: Avacta Group: Preliminary Results for the Year Ended 31 July 2016 32
Apr 25, 2016: Avacta Group: Interim Results for the Period Ended 31 January 2016 34
Corporate Communications 35
Jan 25, 2016: Avacta Appoints Philippe Cotrel as Chief Commercial Officer 35
Government and Public Interest 36
Jan 20, 2017: AGM business update and notice of results 36
Product News 37
Sep 22, 2016: Positive results from first preclinical in-vivo studies of Affimer therapeutics 37
Other Significant Developments 38
Aug 01, 2016: Avacta Group: Pre-close trading update 38
Apr 19, 2016: Affimer Therapeutic Platform Development Milestone Achieved 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Avacta Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Avacta Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Avacta Group Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Avacta Group Plc, Medical Devices Deals, 2011 to YTD 2017 10
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Avacta Group Enters into Agreement with Memorial Sloan Kettering Cancer Center 12
Avacta Enters into Agreement with Glythera 13
Avacta Enters Into Agreement With UbiQ Bio For Ubiquitin Affimers 14
Avacta Life Sciences Enters Into Co-Development Agreement With University of Liverpool 15
Avacta Enters Into Co-Marketing Agreement With Pall 16
Avacta Group Enters Into Distribution Agreement With Cold Spring Biotech 17
Avacta Enters Into Licensing Agreement With Blueberry Therapeutics For Affimers 18
Avacta Announces Private Placement Of Shares For US$17 Million 19
Avacta Group Announces Private Placement Of Shares For US$8.1 Million 21
Avacta Group Completes Private Placement Of US$3 Million 22
Unchained Labs Acquires Optim Technology from Avacta for USD5 Million 23
Avacta Group Completes Acquisition Of Biotech Company Aptuscan For US$2.3 Million 24
Avacta Group Plc, Key Competitors 25
Avacta Group Plc, Key Employees 26
Avacta Group Plc, Other Locations 27
Avacta Group Plc, Subsidiaries 27

★海外企業調査レポート[Avacta Group Plc (AVCT)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MetaStat Inc (MTST):製薬・医療:M&Aディール及び事業提携情報
    Summary MetaStat Inc (MetaStat) is a biotechnology company that discovers and develops personalized diagnostic and therapeutic treatment solutions for cancer patients. The company develops therapeutic product candidates based on novel approach that offers intracellular Mena protein isoforms drugable …
  • Kazia Therapeutics Ltd (KZA):製薬・医療:M&Aディール及び事業提携情報
    Summary Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology platforms, phosphoinositide 3-kinase (PI3K) inhibitors, anti-tropomyosins (A …
  • Bioasis Technologies Inc (BTI):医療機器:M&Aディール及び事業提携情報
    Summary Bioasis Technologies Inc (BTI) is a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents across t …
  • BP Australia Group Pty Ltd:企業の戦略的SWOT分析
    BP Australia Group Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Umicore SA:企業の戦略・SWOT・財務分析
    Umicore SA - Strategy, SWOT and Corporate Finance Report Summary Umicore SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Northern Ireland Electricity Networks Ltd:企業の戦略的SWOT分析
    Northern Ireland Electricity Networks Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • CJ ENM Co Ltd (035760):企業の財務・戦略的SWOT分析
    CJ ENM Co Ltd (035760) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Nutricia GmbH:企業の戦略的SWOT分析
    Nutricia GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • SNCF Mobilites Group:企業の戦略・SWOT・財務情報
    SNCF Mobilites Group - Strategy, SWOT and Corporate Finance Report Summary SNCF Mobilites Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Multan Electric Power Company:発電所・企業SWOT分析
    Multan Electric Power Company – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Falck Renewables S.p.A. (FKR):電力:M&Aディール及び事業提携情報
    Summary Falck Renewables S.p.A. (Falck Renewables), formerly Actelios S.p.A that develops, designs, constructs and manages energy production plants. It operates as a subsidiary of Falck S.p.A. The company produces clean energy from various renewable sources including wind energy, solar energy, bioma …
  • CMI Ltd (CMI):企業の財務・戦略的SWOT分析
    CMI Ltd (CMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Envision Solar International Inc (EVSI):電力:M&Aディール及び事業提携情報
    Summary Envision Solar International Inc (Envision Solar) is a provider of energy security systems. The company's products include renewably energized electric vehicle charging systems, media and branding systems, energy security systems, patented solar tracking systems, energy storage systems, elec …
  • BBVA Banco Frances S.A. (FRAN3):企業の財務・戦略的SWOT分析
    BBVA Banco Frances S.A. (FRAN3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Antares Pharma Inc (ATRS):企業の財務・戦略的SWOT分析
    Antares Pharma Inc (ATRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Bc Hydro:企業の戦略・SWOT・財務分析
    Bc Hydro - Strategy, SWOT and Corporate Finance Report Summary Bc Hydro - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Alps Industries Ltd.:企業の戦略・SWOT・財務分析
    Alps Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary Alps Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Mitochon Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Mitochon Pharmaceuticals Inc (Mitochon Pharma) is a biotech company that develops drugs for neurodegenerative and neuromuscular diseases. The company’s pipeline products comprise mitochondrial modulators such as MP-101, MP-201 and MP-301. It targets diseases such as batten disease, stroke, h …
  • NewOcean Energy Holdings Ltd (342):企業の財務・戦略的SWOT分析
    NewOcean Energy Holdings Ltd (342) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • RGC Resources Inc (RGCO):企業の財務・戦略的SWOT分析
    Summary RGC Resources Inc (RGC Resources) is an energy company that distributes natural gas. The company offers home appliances such as gas furnaces, natural gas water heaters, gas dryers and ranges, gas logs and space heaters, gas generators, gas grills and gas lights, among others. It offers natur …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆